RHHBY - Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline Sees Over 160% Upside | Benzinga
Goldman Sachs has initiated coverage on Regenxbio Inc (NASDAQ:RGNX), citing the potential for the company’s gene therapy platform.
The company’s pipeline includes gene therapy candidates for ophthalmology (wet AMD and diabetic retinopathy), Duchenne muscular dystrophy (DMD), and Hunter syndrome.
The analyst predicts that RGX-314 for wet AMD and diabetic retinopathy will have limited market penetration, primarily serving specific patient subgroups due to the high standards of efficacy and safety set by newer anti-VEGF treatments that require fewer injections, e.g., high dose Regeneron Pharmaceutical Inc’s (NASDAQ:REGN) Eylea, Roche Holdings AG’s (OTC:RHHBY) Vabysmo.